Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes

BACKGROUND AND OBJECTIVES: The therapeutic effects of the dopamine D2 receptor (D2R) agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous system actions. However, peripheral dopamine directly modulates glucose uptake in insulin-sensitive tissues and lipid metaboli...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavares, G., Marques, D., Barra, C., Rosendo-Silva, D., Costa, A., Rodrigues, T., Gasparini, P., Melo, B.F., Sacramento, J.F., Seiça, R., Conde, S.V., Matafome, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164040/
https://www.ncbi.nlm.nih.gov/pubmed/33933677
http://dx.doi.org/10.1016/j.molmet.2021.101241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164040/
https://www.ncbi.nlm.nih.gov/pubmed/33933677
http://dx.doi.org/10.1016/j.molmet.2021.101241

Ejemplares similares